The Maharashtra FDA has suspended the licence of the PPP blood bank at Mumbai’s Dr RN Cooper Hospital. Blood bank services have been suspended from November 5 after regulatory action was taken and suspension will continue till November 7, 2026.
That decision has drawn attention to how blood transfusion services are run at one of Mumbai’s biggest civic-run hospitals. If the facility is temporarily suspended this will make life difficult for patients who rely on it for blood and blood components (e.g. those undergoing surgery or needing transfusions regularly).
The FDA’s action affects the PPP-run blood bank at Cooper Hospital but doesn’t say whether that is what led to licence suspension or if regulatory violations (if any) were involved.
The move comes against the backdrop of increased regulatory scrutiny on blood banks and blood storage facilities across Maharashtra. State FDA has been taking steps to ensure compliance with rules regarding collection, testing, processing, storage and distribution of blood.
Blood banks are regulated under the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. They lay down licensing requirements, qualified staff for donor screening tests procedures for testing storage conditions quality control documentation etc. Compliance is necessary to ensure blood and its components remain safe for patients.
Maharashtra FDA has also issued broader directions to blood centres in the state to review their procedures and compliance with statutory norms. These measures are aimed at increasing transparency and safety standards of blood transfusion services.
Cooper Hospital (formerly Dr RN Cooper Municipal General Hospital) is a major healthcare facility in Mumbai catering to patients. It is a 520-bed multispecialty hospital offering various medical services and is managed by the Brihanmumbai Municipal Corporation (BMC).
The hospital’s blood bank is part of a public private partnership arrangement so the latest suspension was an important development for the hospital’s healthcare operations.
The suspension also raises questions about how patients needing blood and blood products will get them during the pause. Patients scheduled for procedures or those requiring urgent transfusions may need to work with hospital authorities on alternate arrangements.
However, alternative blood supply arrangements were not specified; the number of patients affected; services through other facilities were available or not. This was not confirmed in the reports.
The suspension is scheduled to continue until Nov. 7 and more clarity is needed on the FDA’s decision, the compliance requirements placed on the blood bank and steps needed to get back up and running.
This is an example of why regulation is so important for blood banks: quality, safety and uninterrupted access to essential medical resources are still needed for patient care.
Comments